{"id":2387,"date":"2026-05-25T16:00:40","date_gmt":"2026-05-25T07:00:40","guid":{"rendered":"https:\/\/prismbiolab.com\/?post_type=news&#038;p=2387"},"modified":"2026-05-22T23:35:11","modified_gmt":"2026-05-22T14:35:11","slug":"cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting","status":"publish","type":"news","link":"https:\/\/prismbiolab.com\/ja\/news\/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting\/","title":{"rendered":"PRISM BioLab \u3068\u30a8\u30fc\u30b6\u30a4\u304c\u5171\u540c\u5275\u51fa\u3057\u305fE7386\u3001\u30a8\u30fc\u30b6\u30a4\u304c\u7c73\u56fd\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\uff08ASCO\uff09\u5e74\u6b21\u7dcf\u4f1a\u306b\u3066\u7b2c\u2160\u76f8\u81e8\u5e8a\u8a66\u9a13\u306e\u5fc3\u81d3\u5b89\u5168\u6027\u8a55\u4fa1\u7d50\u679c\u3092\u767a\u8868"},"content":{"rendered":"<p data-renderer-start-pos=\"414\"><span class=\"fabric-text-color-mark\" data-renderer-mark=\"true\" data-text-custom-color=\"#172b4d\">PRISM BioLab\u306f\u3001\u3053\u306e\u5ea6\u3001\u5f53\u793e\u3068\u30a8\u30fc\u30b6\u30a4\u682a\u5f0f\u4f1a\u793e\u306b\u3088\u308a\u5171\u540c\u5275\u51fa\u3055\u308c\u305fE7386\u306b\u3064\u3044\u3066\u30012026\u5e74\uff15\u2f4929\u65e5\u304b\u3089\uff16\u2f49\uff12\u65e5\u307e\u3067\u7c73\u56fd\u30fb\u30a4\u30ea\u30ce\u30a4\u5dde\u30b7\u30ab\u30b4\u306b\u304a\u3044\u3066\u958b\u50ac\u3055\u308c\u308b\u7c73\u56fd\u81e8\u5e8a\u816b\u760d\u5b66\n\u4f1a\uff08American Society of Clinical Oncology : ASCO\uff09\u5e74\u6b21\u7dcf\u4f1a\uff08ASCO Annual Meeting 2026\uff09\u306b\u304a\u3044\u3066\u3001Online Publication Only\u306e\u5f62\u5f0f\u3067\u7b2c\u2160\u76f8\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3051\u308b\u2f3c\u81d3\u5b89\u5168\u6027\u8a55\u4fa1\u306e\u89e3\u6790\u7d50\u679c\u304c\u30a8\u30fc\u30b6\u30a4\u306b\u3088\u308a\u767a\u8868\u3055\u308c\u308b\u3053\u3068\u3092\u304a\u77e5\u3089\u305b\u3044\u305f\u3057\u307e\u3059\u3002<\/span><\/p>\n<p data-renderer-start-pos=\"926\"><span class=\"fabric-text-color-mark\" data-renderer-mark=\"true\" data-text-custom-color=\"#172b4d\">\u8a73\u7d30\u306f <a href=\"https:\/\/prismbiolab.com\/wp-content\/uploads\/2026\/05\/20260525_ASCO_Cardiac-Safety-Evaluation-Results-from-Phase1_jp.pdf\">\u3053\u3061\u3089<\/a>.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>PRISM BioLab today announced that the abstract titled &#8220;Leveraging E7386 phase 1 trials for cardiac safety: gaining concentration-QTc insights to inform early-stage oncology development&#8221; is now available. E7386 is a molecule jointly created by PRISM BioLab and Eisai Co., Ltd. The results will be published as an ASCO Online Publication by Eisai at the American [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","tags":[],"news-category":[8],"class_list":["post-2387","news","type-news","status-publish","hentry","news-category-news","post"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cardiac Safety Evaluation Results from Phase 1 Clinical Studies of E7386, Jointly Created by PRISM BioLab and Eisai, to Be Shared by Eisai at the ASCO Annual Meeting - PRISM BioLab<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/prismbiolab.com\/ja\/news\/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cardiac Safety Evaluation Results from Phase 1 Clinical Studies of E7386, Jointly Created by PRISM BioLab and Eisai, to Be Shared by Eisai at the ASCO Annual Meeting - PRISM BioLab\" \/>\n<meta property=\"og:description\" content=\"PRISM BioLab today announced that the abstract titled &#8220;Leveraging E7386 phase 1 trials for cardiac safety: gaining concentration-QTc insights to inform early-stage oncology development&#8221; is now available. E7386 is a molecule jointly created by PRISM BioLab and Eisai Co., Ltd. The results will be published as an ASCO Online Publication by Eisai at the American [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/prismbiolab.com\/ja\/news\/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"PRISM BioLab\" \/>\n<meta property=\"og:image\" content=\"https:\/\/prismbiolab.com\/wp-content\/uploads\/2024\/07\/career-collage.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1122\" \/>\n\t<meta property=\"og:image:height\" content=\"1097\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/news\\\/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/news\\\/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting\\\/\",\"name\":\"Cardiac Safety Evaluation Results from Phase 1 Clinical Studies of E7386, Jointly Created by PRISM BioLab and Eisai, to Be Shared by Eisai at the ASCO Annual Meeting - PRISM BioLab\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#website\"},\"datePublished\":\"2026-05-25T07:00:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/news\\\/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/prismbiolab.com\\\/news\\\/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/news\\\/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/prismbiolab.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/prismbiolab.com\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Cardiac Safety Evaluation Results from Phase 1 Clinical Studies of E7386, Jointly Created by PRISM BioLab and Eisai, to Be Shared by Eisai at the ASCO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#website\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/\",\"name\":\"PRISM BioLab\",\"description\":\"PRISM BioLab MIMICS natural  peptides leading to cures of the  greatest health challenges\",\"publisher\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/prismbiolab.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#organization\",\"name\":\"PRISM BioLab\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/prism_logo_b.jpg\",\"contentUrl\":\"https:\\\/\\\/prismbiolab.com\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/prism_logo_b.jpg\",\"width\":300,\"height\":367,\"caption\":\"PRISM BioLab\"},\"image\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PRISM BioLab \u3068\u30a8\u30fc\u30b6\u30a4\u304c\u5171\u540c\u5275\u51fa\u3057\u305fE7386\u3001\u30a8\u30fc\u30b6\u30a4\u304c\u7c73\u56fd\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\uff08ASCO\uff09\u5e74\u6b21\u7dcf\u4f1a\u306b\u3066\u7b2c\u2160\u76f8\u81e8\u5e8a\u8a66\u9a13\u306e\u5fc3\u81d3\u5b89\u5168\u6027\u8a55\u4fa1\u7d50\u679c\u3092\u767a\u8868 - PRISM BioLab","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/prismbiolab.com\/ja\/news\/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting\/","og_locale":"ja_JP","og_type":"article","og_title":"Cardiac Safety Evaluation Results from Phase 1 Clinical Studies of E7386, Jointly Created by PRISM BioLab and Eisai, to Be Shared by Eisai at the ASCO Annual Meeting - PRISM BioLab","og_description":"PRISM BioLab today announced that the abstract titled &#8220;Leveraging E7386 phase 1 trials for cardiac safety: gaining concentration-QTc insights to inform early-stage oncology development&#8221; is now available. E7386 is a molecule jointly created by PRISM BioLab and Eisai Co., Ltd. The results will be published as an ASCO Online Publication by Eisai at the American [&hellip;]","og_url":"https:\/\/prismbiolab.com\/ja\/news\/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting\/","og_site_name":"PRISM BioLab","og_image":[{"width":1122,"height":1097,"url":"https:\/\/prismbiolab.com\/wp-content\/uploads\/2024\/07\/career-collage.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/prismbiolab.com\/news\/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting\/","url":"https:\/\/prismbiolab.com\/news\/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting\/","name":"PRISM BioLab \u3068\u30a8\u30fc\u30b6\u30a4\u304c\u5171\u540c\u5275\u51fa\u3057\u305fE7386\u3001\u30a8\u30fc\u30b6\u30a4\u304c\u7c73\u56fd\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\uff08ASCO\uff09\u5e74\u6b21\u7dcf\u4f1a\u306b\u3066\u7b2c\u2160\u76f8\u81e8\u5e8a\u8a66\u9a13\u306e\u5fc3\u81d3\u5b89\u5168\u6027\u8a55\u4fa1\u7d50\u679c\u3092\u767a\u8868 - PRISM BioLab","isPartOf":{"@id":"https:\/\/prismbiolab.com\/#website"},"datePublished":"2026-05-25T07:00:40+00:00","breadcrumb":{"@id":"https:\/\/prismbiolab.com\/news\/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/prismbiolab.com\/news\/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/prismbiolab.com\/news\/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/prismbiolab.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/prismbiolab.com\/news\/"},{"@type":"ListItem","position":3,"name":"Cardiac Safety Evaluation Results from Phase 1 Clinical Studies of E7386, Jointly Created by PRISM BioLab and Eisai, to Be Shared by Eisai at the ASCO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/prismbiolab.com\/#website","url":"https:\/\/prismbiolab.com\/","name":"PRISM BioLab","description":"PRISM BioLab MIMICS natural  peptides leading to cures of the  greatest health challenges","publisher":{"@id":"https:\/\/prismbiolab.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/prismbiolab.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/prismbiolab.com\/#organization","name":"PRISM BioLab","url":"https:\/\/prismbiolab.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/prismbiolab.com\/#\/schema\/logo\/image\/","url":"https:\/\/prismbiolab.com\/wp-content\/uploads\/2021\/09\/prism_logo_b.jpg","contentUrl":"https:\/\/prismbiolab.com\/wp-content\/uploads\/2021\/09\/prism_logo_b.jpg","width":300,"height":367,"caption":"PRISM BioLab"},"image":{"@id":"https:\/\/prismbiolab.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/news\/2387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/comments?post=2387"}],"version-history":[{"count":1,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/news\/2387\/revisions"}],"predecessor-version":[{"id":2388,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/news\/2387\/revisions\/2388"}],"wp:attachment":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/media?parent=2387"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/tags?post=2387"},{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/news-category?post=2387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}